BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Related Keywords

Bern ,Switzerland ,United States ,John Bluth ,Catherine Collier Kyroulis ,Yarlagaddas Babu ,Hintere Gasse ,Exchange Commission ,Biocryst Pharmaceuticals ,Biocryst Pharmaceuticals Inc ,Nasdaq ,Cryst Pharmaceuticals ,European Meeting ,Human Disease ,Oral Factord Inhibitor ,Building Fab ,Annual Report ,Quarterly Reports ,Current Reports ,Covid 19 ,Health ,Business ,Globe Newswire ,